Global Hematologic Malignancies Treatment 麻豆原创 Research Report 2023

Publication ID:

PB501234546

Publication Date:

January 10, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Hematological malignancy, also known as hematological disease, is a type of cancer impacting bone marrow, blood, and lymph nodes. Different sorts of mature blood cells include white blood cells for immune protection, platelets for wound clotting, and red blood cells to carry oxygen. In the bone marrow, it originates from progenitor cells and hematopoietic stem. Hematologic malignancies initiate in these cells and are subcategorized as per the type of blood cell that is affected such as myeloid or myelogenous or and lymphocytic lymphoblastic. A malignancy in the lymphoid lineage involves B lymphocytes and T lymphocytes. Malignancy in the myeloid lineage involves precursor cells to white blood cells platelets and red blood cells.
Highlights
The global Hematologic Malignancies Treatment market was valued at US$ 59010 million in 2022 and is anticipated to reach US$ 204420 million by 2029, witnessing a CAGR of 23.0% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global key hematologic malignancies treatment manufacturers include Bristol-Myers Squibb, Johnson & Johnson, AbbVie etc. The top 3 company hold a share about 60%. North America is the largest market, with a share about 50%, followed by Europe and Asia-Pacific with the share both about 22%. In terms of product, chemotherapy is the largest segment, with a share over 30%. And in terms of application, the largest application is leukemia, followed by lymphoma and multiple听myeloma.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hematologic Malignancies Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hematologic Malignancies Treatment.
The Hematologic Malignancies Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Hematologic Malignancies Treatment market comprehensively. Regional market sizes, concerning products by type, by disease, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hematologic Malignancies Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by disease, and by regions.
By Company
Bristol-Myers Squibb
Johnson & Johnson
AbbVie
Novartis
Roche
Amgen
Takeda
Pfizer
AstraZeneca
Gilead Sciences
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy
Segment by Disease
Leukemia
Lymphoma
Multiple Myeloma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, disease, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hematologic Malignancies Treatment companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by disease, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Hematologic Malignancies Treatment 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy
1.3 麻豆原创 by Disease
1.3.1 Global Hematologic Malignancies Treatment 麻豆原创 Growth by Disease: 2018 VS 2022 VS 2029
1.3.2 Leukemia
1.3.3 Lymphoma
1.3.4 Multiple Myeloma
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hematologic Malignancies Treatment 麻豆原创 Perspective (2018-2029)
2.2 Hematologic Malignancies Treatment Growth Trends by Region
2.2.1 Global Hematologic Malignancies Treatment 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Hematologic Malignancies Treatment Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Hematologic Malignancies Treatment Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Hematologic Malignancies Treatment 麻豆原创 Dynamics
2.3.1 Hematologic Malignancies Treatment Industry Trends
2.3.2 Hematologic Malignancies Treatment 麻豆原创 Drivers
2.3.3 Hematologic Malignancies Treatment 麻豆原创 Challenges
2.3.4 Hematologic Malignancies Treatment 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hematologic Malignancies Treatment Players by Revenue
3.1.1 Global Top Hematologic Malignancies Treatment Players by Revenue (2018-2023)
3.1.2 Global Hematologic Malignancies Treatment Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Hematologic Malignancies Treatment 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hematologic Malignancies Treatment Revenue
3.4 Global Hematologic Malignancies Treatment 麻豆原创 Concentration Ratio
3.4.1 Global Hematologic Malignancies Treatment 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematologic Malignancies Treatment Revenue in 2022
3.5 Hematologic Malignancies Treatment Key Players Head office and Area Served
3.6 Key Players Hematologic Malignancies Treatment Product Solution and Service
3.7 Date of Enter into Hematologic Malignancies Treatment 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Hematologic Malignancies Treatment Breakdown Data by Type
4.1 Global Hematologic Malignancies Treatment Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Hematologic Malignancies Treatment Forecasted 麻豆原创 Size by Type (2024-2029)
5 Hematologic Malignancies Treatment Breakdown Data by Disease
5.1 Global Hematologic Malignancies Treatment Historic 麻豆原创 Size by Disease (2018-2023)
5.2 Global Hematologic Malignancies Treatment Forecasted 麻豆原创 Size by Disease (2024-2029)
6 North America
6.1 North America Hematologic Malignancies Treatment 麻豆原创 Size (2018-2029)
6.2 North America Hematologic Malignancies Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Hematologic Malignancies Treatment 麻豆原创 Size by Country (2018-2023)
6.4 North America Hematologic Malignancies Treatment 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hematologic Malignancies Treatment 麻豆原创 Size (2018-2029)
7.2 Europe Hematologic Malignancies Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Hematologic Malignancies Treatment 麻豆原创 Size by Country (2018-2023)
7.4 Europe Hematologic Malignancies Treatment 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hematologic Malignancies Treatment 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Hematologic Malignancies Treatment 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Hematologic Malignancies Treatment 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Hematologic Malignancies Treatment 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hematologic Malignancies Treatment 麻豆原创 Size (2018-2029)
9.2 Latin America Hematologic Malignancies Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Hematologic Malignancies Treatment 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Hematologic Malignancies Treatment 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hematologic Malignancies Treatment 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Hematologic Malignancies Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Hematologic Malignancies Treatment 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Hematologic Malignancies Treatment 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Hematologic Malignancies Treatment Introduction
11.1.4 Bristol-Myers Squibb Revenue in Hematologic Malignancies Treatment Business (2018-2023)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson Hematologic Malignancies Treatment Introduction
11.2.4 Johnson & Johnson Revenue in Hematologic Malignancies Treatment Business (2018-2023)
11.2.5 Johnson & Johnson Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Hematologic Malignancies Treatment Introduction
11.3.4 AbbVie Revenue in Hematologic Malignancies Treatment Business (2018-2023)
11.3.5 AbbVie Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Hematologic Malignancies Treatment Introduction
11.4.4 Novartis Revenue in Hematologic Malignancies Treatment Business (2018-2023)
11.4.5 Novartis Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Hematologic Malignancies Treatment Introduction
11.5.4 Roche Revenue in Hematologic Malignancies Treatment Business (2018-2023)
11.5.5 Roche Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Hematologic Malignancies Treatment Introduction
11.6.4 Amgen Revenue in Hematologic Malignancies Treatment Business (2018-2023)
11.6.5 Amgen Recent Development
11.7 Takeda
11.7.1 Takeda Company Detail
11.7.2 Takeda Business Overview
11.7.3 Takeda Hematologic Malignancies Treatment Introduction
11.7.4 Takeda Revenue in Hematologic Malignancies Treatment Business (2018-2023)
11.7.5 Takeda Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Hematologic Malignancies Treatment Introduction
11.8.4 Pfizer Revenue in Hematologic Malignancies Treatment Business (2018-2023)
11.8.5 Pfizer Recent Development
11.9 AstraZeneca
11.9.1 AstraZeneca Company Detail
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Hematologic Malignancies Treatment Introduction
11.9.4 AstraZeneca Revenue in Hematologic Malignancies Treatment Business (2018-2023)
11.9.5 AstraZeneca Recent Development
11.10 Gilead Sciences
11.10.1 Gilead Sciences Company Detail
11.10.2 Gilead Sciences Business Overview
11.10.3 Gilead Sciences Hematologic Malignancies Treatment Introduction
11.10.4 Gilead Sciences Revenue in Hematologic Malignancies Treatment Business (2018-2023)
11.10.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Bristol-Myers Squibb
Johnson & Johnson
AbbVie
Novartis
Roche
Amgen
Takeda
Pfizer
AstraZeneca
Gilead Sciences

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.